

# Renato De Vecchis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3897753/publications.pdf>

Version: 2024-02-01

84  
papers

607  
citations

687363  
13  
h-index

794594  
19  
g-index

99  
all docs

99  
docs citations

99  
times ranked

1159  
citing authors

#	ARTICLE	IF	CITATIONS
1	Distrust of the new non-citational metrics must be overcome: how to give the appropriate value not only to citing, but also to clicking. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 109-110.	0.7	0
2	Pill-in-the-pocket therapy for paroxysmal atrial fibrillation: a revival of interest for an old approach in the area of antiarrhythmic strategies. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 121-123.	0.7	0
3	Authorship growth and self-citations: two ways for inflating the H-index in contemporary medical literature?. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 326.	1.5	1
4	Authorship growth and self-citations: a scholarly expedient that demonstrates that the use of the metrics for career decisions generates malpractice and misbehavior?. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 619-620.	0.7	0
5	Advancements in the diagnostic workup, prognostic evaluation, and treatment of takotsubo syndrome. <i>Heart Failure Reviews</i> , 2020, 25, 757-771.	3.9	11
6	A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2095218.	0.3	8
7	Alternative metrics to assess the quality and impact at the level of the individual article: how to go beyond the conventional criteria of judgment without citing a given article, but simply by “clicking” on it. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 837.	1.5	0
8	Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan. <i>Cardiology Research</i> , 2020, 11, 213-218.	1.1	12
9	Favorable Effects of Sacubitril/Valsartan on the Peak Atrial Longitudinal Strain in Patients With Chronic Heart Failure and a History of One or More Episodes of Atrial Fibrillation: A Retrospective Cohort Study. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 100-107.	1.2	20
10	Thyrotoxic dilated cardiomyopathy: personal experience and case collection from the literature. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, .	0.5	5
11	Problemas Relacionados À Trombocitopenia em Pacientes com Fibrilação Atrial Concomitante que Necessitam de Prevenção Antitrombótica: Um Estudo de Coorte Retrospectivo. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 717-718.	0.8	0
12	Is sacubitril/valsartan safe for treatment of hypertension at any age?. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 49.	1.5	1
13	High Prevalence of Proarrhythmic Events in Patients With History of Atrial Fibrillation Undergoing a Rhythm Control Strategy: A Retrospective Study. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 345-352.	1.2	6
14	Similar outcome of heart failure with reduced EF patients with and without atrial fibrillation: considerations from the ESC Heart Failure Long-Term Registry. <i>Monaldi Archives for Chest Disease</i> , 2019, 89, .	0.6	0
15	Is an elevated burden of antiarrhythmic drug (AAD) side-effects the unavoidable price to be traded for a durable suppression of AF relapses in ablated patients? The weaknesses and risks of the AAD suppression algorithm used by current models of AF secondary prevention after catheter ablation. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 873-874.	1.9	0
16	Promising effects of moderate-dose corticosteroid therapy in the blanking period for prevention of atrial fibrillation (AF) recurrences in patients undergoing AF ablation. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1179-1180.	1.9	2
17	HFREF Patients and Atrial Fibrillation: Time to Reconsider the Appropriateness of the Atrial Fibrillation Ablation in This Patient Subset?. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 383-384.	2.6	0
18	Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. <i>Heart Failure Reviews</i> , 2019, 24, 521-533.	3.9	23

#	ARTICLE	IF	CITATIONS
19	Atrial mechanical hypofunction after electrical cardioversion of persistent or long-lasting persistent atrial fibrillation: a retrospective cohort study. Monaldi Archives for Chest Disease, 2019, 89, .	0.6	0
20	Conversion to and maintenance of sinus rhythm do not yield a significant increase in stroke-volume in HFREF patients, whose heart works on the flat branch of Frank's Starling curve, thereby making the retrieval of the atrial mechanical contribution in this subset a substantially futile choice. European Heart Journal, 2019, 40, 3651-3652.	2.2	2
21	In heart failure with reduced ejection fraction patients's left ventricular global longitudinal strain is enhanced after 1-year therapy with sacubitril/valsartan compared with conventional therapy with angiotensin-converting enzyme-inhibitors or AT1 blockers. Journal of Cardiovascular Medicine, 2019, 20, 857-858.	1.5	2
22	Long-term antiarrhythmic drug treatment after atrial fibrillation ablation: does a too obstinate rhythm control strategy bring serious risk of proarrhythmia to ablated patients?. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 117-118.	3.0	3
23	CABANA trial: disappointing results?. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 57-57.	3.0	1
24	Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction. Herz, 2019, 44, 425-432.	1.1	24
25	Cognitive performance of patients with chronic heart failure on sacubitril/valsartan. Herz, 2019, 44, 534-540.	1.1	16
26	In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization. Herz, 2019, 44, 651-658.	1.1	7
27	A Case of Fatal Intestinal Infarct Preceded by Recurrent Ischaemic Colitis due to the Enterotoxic Effect of Sodium Polystyrene Sulfonate. European Journal of Case Reports in Internal Medicine, 2019, 8, 001973.	0.4	0
28	Anti-Hypertensive Effect of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials. Cardiology Research, 2019, 10, 24-33.	1.1	16
29	Rate Control Yields Better Clinical Outcomes Over a Median Follow-Up of 20 Months Compared to Rhythm Control Strategy in Patients With a History of Atrial Fibrillation: A Retrospective Cohort Study. Cardiology Research, 2019, 10, 98-105.	1.1	3
30	Sacubitril/Valsartan Therapy for 14 Months Induces a Marked Improvement of Global Longitudinal Strain in Patients With Chronic Heart Failure: A Retrospective Cohort Study. Cardiology Research, 2019, 10, 293-302.	1.1	13
31	Antihypertensive effect of sacubitril/valsartan: a meta-analysis. Minerva Cardioangiologica, 2019, 67, 214-222.	1.2	10
32	Ablation, rate or rhythm control strategies for patients with atrial fibrillation: how do they affect mid-term clinical outcomes?. Minerva Cardioangiologica, 2019, 67, 272-279.	1.2	1
33	Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction. Minerva Cardioangiologica, 2019, 67, 456-463.	1.2	11
34	Secondary Prevention of Nonvalvular Atrial Fibrillation: A Retrospective Cohort Study. Cardiology Research, 2019, 10, 223-229.	1.1	2
35	Addressing the Challenge of Atrial Fibrillation Management: How to Differentiate the Approach Depending on Left Ventricular Ejection Fraction. Cardiology Research, 2019, 10, 253-254.	1.1	0
36	Is Left Atrial Appendage Occlusion Really Efficacious in Avoiding Administering Anticoagulant Drugs for the Prevention of Cardioembolic Events in Patients With Atrial Fibrillation?. Journal of Clinical Medicine Research, 2019, 11, 664-665.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Secondary Prevention of Atrial Fibrillation: Is It Worth Doing?. Journal of Clinical Medicine Research, 2019, 11, 309.	1.2	0
38	Network meta-analysis: a new analysis tool of the experimental evidence. Minerva Medica, 2019, 110, 173-175.	0.9	0
39	Effects of dronedarone on all-cause mortality and on cardiovascular events in patients treated for atrial fibrillation: a meta-analysis of RCTs. Minerva Cardioangiologica, 2019, 67, 163-171.	1.2	2
40	Diuretic dosing in heart failure: more data are needed. ESC Heart Failure, 2018, 5, 649-650.	3.1	3
41	Use of newly designed graphs for depicting network meta-analyses. Journal of Cardiovascular Medicine, 2018, 19, 681-683.	1.5	0
42	Malignant Ventricular Arrhythmias Resulting From Drug-Induced QTc Prolongation: A Retrospective Study. Journal of Clinical Medicine Research, 2018, 10, 593-600.	1.2	2
43	Acquired drug-induced long QTc: new insights coming from a retrospective study. European Journal of Clinical Pharmacology, 2018, 74, 1645-1651.	1.9	5
44	Illustrating the Sense of a Network Meta-Analysis by Means of Dedicated Plots: A Way for Making It Conceptually Easier and More Immediately Understandable. Journal of Clinical Medicine Research, 2018, 10, 732-735.	1.2	2
45	Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis. Minerva Cardiology and Angiology, 2018, 66, 349-359.	0.7	6
46	Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis. Minerva Cardioangiologica, 2018, 66, 659-670.	1.2	8
47	A New Approach for Hypertension: the Case of Sacubitril/Valsartan Experienced in Randomized Controlled Trials That Selectively Restrict Its Use to the Hypertension of the Elderly. Journal of Clinical Medicine Research, 2018, 10, 853-854.	1.2	3
48	Transcatheter closure of PFO as secondary prevention of cryptogenic stroke. Herz, 2017, 42, 45-50.	1.1	7
49	Comorbidity “depression” in heart failure “Potential target of patient education and self-management. BMC Cardiovascular Disorders, 2017, 17, 48.	1.7	8
50	Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis. Interventional Medicine & Applied Science, 2017, 9, 123-135.	0.2	2
51	Prognostic value of clinical, echocardiographic and angiographic indicators in patients with large anterior ST-segment elevation myocardial infarction as a first acute coronary event. Journal of Cardiovascular Medicine, 2017, 18, 946-953.	1.5	3
52	Vasopressin receptor antagonists in patients with chronic heart failure. Herz, 2017, 42, 492-497.	1.1	4
53	Platypnea “orthodeoxia syndrome. Herz, 2017, 42, 384-389.	1.1	9
54	Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?. Journal of Clinical Medicine Research, 2017, 9, 266-272.	1.2	8

#	ARTICLE	IF	CITATIONS
55	Natriuretic peptide-guided versus clinically guided therapy for chronic heart failure: careful expert clinical management can remove need for biomarker-tailored dosing adjustment. <i>Journal of Thoracic Disease</i> , 2017, 9, 4137-4140.	1.4	0
56	The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 130-142.	1.2	5
57	Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 488-498.	1.2	28
58	Thiazides and Osteoporotic Spinal Fractures: A Suspected Linkage Investigated by Means of a Two-Center, Case-Control Study. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 943-949.	1.2	6
59	Differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction—results of a meta-analysis of randomized controlled trials. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 272-287.	1.7	3
60	Ranolazine and TDM1 treatment: Cardioprotective effects in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23102-e23102.	1.6	0
61	Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials. <i>Minerva Cardiology and Angiology</i> . 2017. 65, 427-442.	0.7	1
62	Effects of Hyponatremia Normalization on the Short-Term Mortality and Rehospitalizations in Patients with Recent Acute Decompensated Heart Failure: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2016, 5, 92.	2.4	15
63	Platypnea—“Orthodeoxia Syndrome: Multiple Pathophysiological Interpretations of a Clinical Picture Primarily Consisting of Orthostatic Dyspnea. <i>Journal of Clinical Medicine</i> , 2016, 5, 85.	2.4	24
64	Clinical Relevance of Anticoagulation and Dual Antiplatelet Therapy to the Outcomes of Patients With Atrial Fibrillation and Recent Percutaneous Coronary Intervention With Stent. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 153-161.	1.2	24
65	Effects of limiting fluid intake on clinical and laboratory outcomes in patients with heart failure. <i>Herz</i> , 2016, 41, 63-75.	1.1	21
66	Measuring B-Type Natriuretic Peptide From Capillary Blood or Venous Sample: Is It the Same?. <i>Cardiology Research</i> , 2016, 7, 51-58.	1.1	6
67	Unresolved or Contradictory Issues About Management of Patients With Patent Foramen Ovale and Previous Cryptogenic Stroke: Additional Randomized Controlled Trials Are Eagerly Awaited. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 361-366.	1.2	4
68	Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson’s Disease Patients: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 449-460.	1.2	7
69	Estimating Right Atrial Pressure Using Ultrasounds: An Old Issue Revisited With New Methods. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 569-574.	1.2	17
70	Change of Serum BNP Between Admission and Discharge After Acute Decompensated Heart Failure Is a Better Predictor of 6-Month All-Cause Mortality Than the Single BNP Value Determined at Admission. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 737-742.	1.2	8
71	The MacNew Questionnaire Is a Helpful Tool for Predicting Unplanned Hospital Readmissions After Coronary Revascularization. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 210-214.	1.2	1
72	Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data. <i>Anatolian Journal of Cardiology</i> , 2015, 16, 2-9.	0.9	29

#	ARTICLE	IF	CITATIONS
73	The Relation Between Global Longitudinal Strain and Serum Natriuretic Peptide Is More Strict Than That Found Between the Latter and Left Ventricular Ejection Fraction: A Retrospective Study in Chronic Heart Failure. Journal of Clinical Medicine Research, 2015, 7, 979-988.	1.2	10
74	Inferior vena cava and hemodynamic congestion. Research in Cardiovascular Medicine, 2015, 4, 3.	0.1	17
75	Cardiorenal syndrome type 2: from diagnosis to&nbsp;optimal management. Therapeutics and Clinical Risk Management, 2014, 10, 949.	2.0	19
76	B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure. Journal of Cardiovascular Medicine, 2014, 15, 122-134.	1.5	38
77	Statin use for nonrheumatic calcific aortic valve stenosis. Journal of Cardiovascular Medicine, 2013, 14, 559-567.	1.5	10
78	Ultrasound evaluation of the inferior vena cava collapsibility index in congestive heart failure patients treated with intravenous diuretics: new insights about its relationship with renal function: An observational study. Anatolian Journal of Cardiology, 2012, 12, 391-400.	0.4	9
79	Colapsibilidade da Veia Cava Inferior e sinais e sintomas de insuficiência cardíaca: novos insights e possíveis associações. Arquivos Brasileiros De Cardiologia, 2012, 98, 544-552.	0.8	4
80	The Relation Between Carotid Atherosclerotic Plaques and Ischemic Stroke Is Critically Conditioned by the Role of Arterial Hypertension as an Effect Modifier. Canadian Journal of Cardiology, 2011, 27, 152-158.	1.7	2
81	Terapia com inibidor da ECA com dosagens relativamente altas e risco de agravamento renal na insuficiência cardíaca crônica. Arquivos Brasileiros De Cardiologia, 2011, 97, 507-516.	0.8	2
82	Reply: intravenous loop diuretics versus isolated ultrafiltration for chronic congestive heart failure: competition or integration?. Journal of Cardiovascular Medicine, 2011, 12, 3-4.	1.5	0
83	Intima-media thickness of internal carotid arteries and total carotid plaque area: two surrogate endpoints of which the former has to be considered a weaker putative measure of subclinical atherosclerosis compared with the latter. Journal of Cardiovascular Medicine, 2010, 11, 325.	1.5	4
84	Unloading therapy by intravenous diuretic in chronic heart failure: a double-edged weapon?. Journal of Cardiovascular Medicine, 2010, Publish Ahead of Print, 571-4.	1.5	8